Early development of osteoporosis in male smokers with hypoandrogenism due to fascioliasis with or without schistosomiasis added by life style.
The multifactor outcome of hypoandrogenemia with the impact of oxidative stress induced by glucose intolerance, fascioliasis with or without schistosomiasis and cumulative smoking influence on bone remodeling and the early development of osteoporotic manifestations were studied. The effect on vascular endothelium immune mediated mechanisms and antioxidant capacity were monitored in cases of youth aged selected male smokers involving 20 with hypoandrogenemia who were either subjected to sedentary life style, glucose intolerance fascioliasis hepatic fibrosis (FHF) (G1) or without (G2) and GI after following 6 months therapy (G3). Monitoring of clinical picture and biochemical assessments of osteoporotic indices (osteocolcin, bone alkaline phosphatase, parathyroid hormone, urinary cyclic AMP), hypoandrogenism (dehydroepiandrosterane sulphate or DHEAS & testosterone) glycemic determinant (insulin) immuno-inflammatory response (interleukein-6, tumor necrosis factor alpha, E-selectin, ceruloplasmin) smoking index (serum cotinine), total antioxidant capacity (AOC) and lipid peroxidation (malonedialdehyde) was done before and after 6 months therapeutic program involving supplement of DHEAS, mirazid, chromium picolinate, and megavit zinc alongside smoking cessation and physical exercise daily for at least 30 minutes. Treatment with Mirazid supplied as 10 mg/kg for 6 successive days resulted in 100% cure of fascioliasis whether single or combined with schistosomiasis.
Kilany
Yasser Fouad
YF
Department of Tropical Medicine, Faculty of Medicine, Al Azhar University, Cairo, Egypt.
Abou Holw
Sahar A
SA
Abouel-Nour
Mohamed Fathy
MF
Morsy
Ayman T A
AT
D000328:Adult; D000728:Androgens / Q000097:blood; D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use; D000975:Antioxidants / Q000378:metabolism; D029744:Commiphora / Q000737:chemistry; D015897:Comorbidity; D004534:Egypt / Q000453:epidemiology; D015444:Exercise; D005211:Fascioliasis / Q000188:drug therapy / Q000453:epidemiology* / Q000378:metabolism; D005947:Glucose / Q000378:metabolism; D006801:Humans; D007006:Hypogonadism / Q000453:epidemiology* / Q000378:metabolism; D008019:Life Style; D008297:Male; D010024:Osteoporosis / Q000453:epidemiology* / Q000378:metabolism; D018384:Oxidative Stress; D008517:Phytotherapy; D010936:Plant Extracts / Q000627:therapeutic use; D012552:Schistosomiasis / Q000188:drug therapy / Q000453:epidemiology* / Q000378:metabolism; D012907:Smoking / Q000009:adverse effects*
D000728:Androgens; D000871:Anthelmintics; D000975:Antioxidants; D010936:Plant Extracts; D005947:Glucose